Starling Oncology, Inc. (STLN) stock

STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/30

$3.50−0.25 (-6.67%)

Close on Nov 13, 2026Market cap $356.71MP/E –Yield –

Starling Oncology statistics

81 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Mar 11, 2027 (estimated, during market hours)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $356.71M; $1.68B
Enterprise Value: $392.33M; $2.20B
PS Ratio: 0.57; 1.53
P/FCF Ratio: 18.95; 19.86
P/OCF Ratio: 15.44; 14.68

Enterprise valuationIndustry

EV / Sales: 0.63; 1.67
EV / FCF: 20.84; 24.49

Share statisticsIndustry

Shares Outstanding: 102M; 59M
Shares Change (YoY): 19.7%; 2.40%
Shares Change (QoQ): 1.51%; 0.33%
Float: 44M; 34M
Shares Held by Insiders: 56.6%; 15.4%
Shares Held by Institutions: 43.4%; 83.6%

Short sellingIndustry

Short Interest: 7M; –
Short Interest Change: 4.67%; -0.86%
Days to Cover: 5.42; 4.41

Stock price statisticsIndustry

52-Week High: $7.13; –
52-Week Low: $2.32; –
20-Day Moving Average: $5.79; –
50-Day Moving Average: $6.23; –
200-Day Moving Average: $4.78; –
Average True Range (14): $0.60; –
Price Change (1 Week): -3.31%; 0.23%
Price Change (1 Month): -49.3%; -0.02%
Price Change (3 Months): -44.5%; 2.13%
Price Change (6 Months): -12.1%; 17.6%
Price Change (YTD): -1.69%; 5.22%
Price Change (1 Year): 2.04%; 3.75%
Price Change (3 Years): 45.2%; 15.2%
Price Change (5 Years): -68.1%; -14.6%
Average Volume (10 Days): 8M; –
Average Volume (20 Days): 4M; –
Average Volume (90 Days): 2M; –
Relative Volume: 11.42; 0.70
Relative Strength Index (14): 29.3; 46.0
Volatility (1 Year): 93.8%; 64.2%
Beta (5 Years): 1.69; 0.76

MarginsIndustry

Operating Margin: -3.39%; -2.98%
Pretax Margin: -5.73%; 2.12%
Profit Margin: -5.73%; -2.01%
EBITDA Margin: -2.32%; 3.36%
FCF Margin: 3.03%; 2.98%

Returns on capitalIndustry

Return on Assets (ROA): -20.2%; -3.10%
Return on Invested Capital (ROIC): -96.2%; 4.69%
Return on Capital Employed (ROCE): -32.8%; 0.40%

Financial positionIndustry

Current Ratio: 1.11; 1.41
Quick Ratio: 0.79; 0.99
Debt / FCF: 3.85; 4.01
Interest Coverage: -2.02; -0.63

GrowthIndustry

Revenue Growth (YoY): 34.6%; 9.63%
Revenue Growth (3Y CAGR): 25.8%; 11.3%
Revenue Growth (5Y CAGR): 21.8%; 12.6%

EfficiencyIndustry

Asset Turnover: 3.53; 0.81
Revenue Per Employee: $967.94K; $235.26K
Profits Per Employee: -$55.44K; -$5.12K
Employee Count: 641; 910
WACC: 13.2%; 8.40%

Income statement (TTM)Industry

Revenue: $620.45M; $638.13M
Operating Income: -$21.02M; -$675.66K
Pretax Income: -$35.54M; -$575.82K
Net Income: -$35.54M; -$1.48M
EBITDA: -$14.41M; $1.17M
EPS (Diluted): -$0.29; -$0.02

Balance sheetIndustry

Cash & Short-Term Investments: $36.90M; $98.48M
Total Debt: $72.52M; $258.06M
Net Cash (Debt): -$35.63M; $203.66K
Net Cash Per Share: -$0.35; $0.00
Equity (Book Value): -$37.36M; $235.60M
Book Value Per Share: -$0.37; $3.91
Tangible Book Value: -$53.45M; $1.59M
Working Capital: $13.99M; $30.06M

Cash flow (TTM)Industry

Operating Cash Flow: $23.10M; $25.90M
Capital Expenditures: -$4.27M; -$15.83M
Free Cash Flow: $18.83M; $18.83M
FCF Per Share: $0.18; $0.36

Dividends and yieldsIndustry

Earnings Yield: -9.96%; 0.19%
FCF Yield: 5.28%; 2.55%

Taxes and interestIndustry

Interest Expense: $10.41M; $7.37M
Income Tax: $0; $564.50K

Scores and fair valueIndustry

Altman Z-Score: 1.74; 2.24
Piotroski F-Score: 3; 5

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	STLN	S&P 500	Difference	STLN per year	S&P 500 per year
1 month	-47.8%	-3.0%	−44.7 pts
3 months	-44.1%	-2.8%	−41.3 pts
Year to date	-1.7%	+11.5%	−13.2 pts
1 year	+13.6%	+13.5%	+0.2 pts
3 years	+37.3%	+77.7%	−40.4 pts	+11.1%	+21.1%
5 years	-68.1%	+72.6%	−140.7 pts	-20.4%	+11.5%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

7M STLN shares were sold short on Oct 30, 2026, up 4.7% from the previous report. At recent volumes it would take 5.4 days to buy them back. Over the last 20 sessions, 26.1% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	6,840,807	+4.7%	1,263,262	5.4
Oct 15, 2026	6,535,739	-3.8%	1,162,698	5.6
Sep 30, 2026	6,793,070	-3.7%	1,576,787	4.3
Sep 15, 2026	7,053,920	+3.5%	959,365	7.3
Aug 31, 2026	6,816,792	-1.0%	1,220,823	5.6
Aug 14, 2026	6,884,302	-3.8%	1,958,837	3.5

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Starling Oncology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is STLN.

Compare: STLN vs CCM · STLN vs SBC · STLN vs LFMD · STLN vs TDOC · STLN vs AUNA

Revenue growth34.6% · median -2.4%

Operating margin-3.4% · median -6.6%

Net margin-5.7% · median 0.2%

Company	Revenue	Growth
TDOC	$2.47B	-2.4%
STLN	$620.45M	+34.6%
LFMD	$189.26M	+23.6%
SBC	$175.17M	-6.9%
CCM	–	–
AUNA	–	–

Company

Next earnings (est.): Mar 11, 2027, during market hours
Exchange: Nasdaq
Industry: Services-Offices & Clinics of Doctors of Medicine
Fiscal year ends: December 31
Employees: 641
Auditor: BDO USA, P.C.
SEC CIK: 1799191

Advertisement
300 × 250

See a number that looks wrong?